Clinical Trials Browser

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, Recurrence, Central Nervous System Neoplasms

NCT02613962 2026-04-01

MAPPYACTS

Phase NA Completed

791 enrolled

Neoplasms, Recurrence

NCT05564650 2025-12-08

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Phase 1 Active not recruiting

6 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT02595866 2024-08-09

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

Phase 1 Completed

58 enrolled 17 charts

DermatologicGastrointestinalLymphoidSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Sarcoma, Kaposi, HIV Infections

NCT00408252 2019-09-19

Efficacy of SU 011248 in Head And Neck Carcinoma

Phase 2 Terminated

54 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Recurrence

NCT01289522 2017-05-15

TPEx

Phase 2 Completed

54 enrolled 9 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

Clinical Trials

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

MAPPYACTS

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

Efficacy of SU 011248 in Head And Neck Carcinoma

TPEx